![](https://cdn.sanity.io/images/0vv8moc6/oncnurse/6c2731f9acaa522f39e4c08dd1642c1836ec3fb5-500x275.png?fit=crop&auto=format)
Celecoxib Plus Adjuvant Chemo Provides Survival Benefit for PIK3CA-Mutated Stage III Colon Cancer
Adding the COX-2 inhibitor celecoxib to standard adjuvant chemotherapy provided a survival benefit—particularly disease-free survival and overall survival— to patients with PIK3CA-activated stage III colon cancer, according to findings from the phase 3 …